Mdma molecule:

Image from PubChem

Mdma Clinical Trials

Emergency Department-Initiated Buprenorphine Validation Network Trial

To see complete record on, please visit this link

Id: NCT04225598

Organisation Name: Yale University

Overal Status: Recruiting

Start Date: July 8, 2020

Last Update: December 2, 2022

Lead Sponsor: Yale University

Brief Summary: This study will (1) recruit, train and provide resources to approximately 30 Emergency Department (ED) sites throughout the U.S. using implementation facilitation strategies to provide ED-initiated buprenorphine (BUP) for patients presenting with opioid use disorder (OUD) who are not receiving medications for opioid use disorder (MOUD). Once implementation is adequately achieved, the sites will (2) conduct a randomized controlled trial (RCT) to compare the effectiveness of sublingual buprenorphine (SL-BUP) versus extended-release buprenorphine (XR-BUP) on ED patients' engagement in formal addiction treatment 7-days after their ED visit. In addition, in an ancillary component of the study, the investigators will (3) assess the use of XR-BUP in ED patients with Clinical Opioid Withdrawal Scale (COWS) scores < 8 in a case series to potentially expand the eligibility of patients in the larger RCT to those presenting with little to no opioid withdrawal symptoms. Finally, the investigators will (4) develop and validate ED electronic health record (EHR) opioid-related phenotypes, both of which will inform the main RCT.

  • Opioid-use Disorder

Total execution time in seconds: 0.2043080329895